A total of 37 Private Equity/Venture Financing deals (pending and completed) were announced in the Pharmaceuticals of France, in the last twelve months resulting in a total deal value of over $1,225.8 million. In the LTM period, March 2022 turned out to be the most prolific in terms of deal size, with a total deal value of $366.1 million, resulting in an average deal value of $73.2 million during that month. On the other hand, the month of September 2021 was the most prolific in terms of deal volume, recording a total of 6 deals, resulting in an average deal value of $53.7 million during that month.
Of the 37 deals, the deal secured between Blackstone Life Sciences Advisors LLC and Sanofi, was the largest Private Equity/Venture Financing deal in the France Pharmaceuticals sector, which was valued at $328.3 million and was completed on March 15, 2022. The second-largest deal was between Banque Populaire Mediterranee; BNP Paribas SA; Bpifrance (France); Credit Agricole Alpes Provence; Societe Generale SA; Tikehau Capital SCA and Provepharm life Solutions SA, while the third-largest deal was between Agent Capital LLC; Alexandria Venture Investments; Andera Partners; Boehringer Ingelheim Venture Fund; Earlybird Venture Capital GmbH & Co KG; Eurazeo SA; Gimv NV; InnoBio 2; Kurma Partners SA; Large Venture; Life Sciences Partners BV; Pfizer Venture Investments; Pureos Partners AG; Wellington Partners and ImCheck Therapeutics SAS. The Banque Populaire Mediterranee; BNP Paribas SA; Bpifrance (France); Credit Agricole Alpes Provence; Societe Generale SA; Tikehau Capital SCA-Provepharm life Solutions SA deal and the Agent Capital LLC; Alexandria Venture Investments; Andera Partners; Boehringer Ingelheim Venture Fund; Earlybird Venture Capital GmbH & Co KG; Eurazeo SA; Gimv NV; InnoBio 2; Kurma Partners SA; Large Venture; Life Sciences Partners BV; Pfizer Venture Investments; Pureos Partners AG; Wellington Partners-ImCheck Therapeutics SAS deal were valued at $142.3 million and $103.0 million, respectively. The fourth-largest deal was between Alexandria Venture Investments; Casdin Capital LLC; Emerson Collective LLC; Redmile Group LLC; Sofinnova Partners SAS-Mnemo Therapeutics SAS valued at $90.9 million, whereas the deal between Andera Partners; ATEM Capital LLC; Credit Agricole Creation SASU; Eurazeo SA; InnoBio 2; Kurma Partners SA; Life Sciences Partners BV; Mass General Brigham Inc; Novo Ventures (US) Inc; Orbimed Advisors LLC; Pontifax Ltd; Sectoral Asset Management Inc; Sham Innovation Sante SAS; Turenne Capital Partners-Amolyt Pharma valued at $80.0 million was the fifth-largest deal.
Cumulatively, the top five deals amounted to $744.5 million and accounted for nearly 60.74% of the total deals (by value) announced during the last twelve months.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward